DK1185294T3 - Peptides for the treatment of attenuated interpersonal and behavioral disorders - Google Patents

Peptides for the treatment of attenuated interpersonal and behavioral disorders

Info

Publication number
DK1185294T3
DK1185294T3 DK00947924T DK00947924T DK1185294T3 DK 1185294 T3 DK1185294 T3 DK 1185294T3 DK 00947924 T DK00947924 T DK 00947924T DK 00947924 T DK00947924 T DK 00947924T DK 1185294 T3 DK1185294 T3 DK 1185294T3
Authority
DK
Denmark
Prior art keywords
disorders
treatment
interpersonal
environment
attenuated
Prior art date
Application number
DK00947924T
Other languages
Danish (da)
Inventor
Tony Marcel
Francois Rougeon
Catherine Rougeot
Original Assignee
Centre Nat Rech Scient
Pasteur Institut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre Nat Rech Scient, Pasteur Institut filed Critical Centre Nat Rech Scient
Application granted granted Critical
Publication of DK1185294T3 publication Critical patent/DK1185294T3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Radiation-Therapy Devices (AREA)
  • Quinoline Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

The invention relates to the field of psychopharmacology. More particularly, the invention relates to the treatment of DSM-III disorders, such as impaired interpersonal and behavioral disorders, including sexual disorders such as M.E.D. and HS.D.D. The invention provides new therapeutic compositions and methods for treating DSM-III disorders, including M.E.D. and H.S.D.D. The compositions and methods according to the invention provide improved awareness and alertness to environment, improved adaptation to environment and ability to sustain attention, and increased interest in environment and capacity for arousal, without increased aggressiveness.
DK00947924T 1999-06-23 2000-06-22 Peptides for the treatment of attenuated interpersonal and behavioral disorders DK1185294T3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14056399P 1999-06-23 1999-06-23
PCT/EP2000/006259 WO2001000221A2 (en) 1999-06-23 2000-06-22 Therapeutic methods and compositions for the treatment of impaired interpersonal and behavioral disorders
EP00947924A EP1185294B1 (en) 1999-06-23 2000-06-22 Peptides for the treatment of impaired interpersonal and behavioral disorders

Publications (1)

Publication Number Publication Date
DK1185294T3 true DK1185294T3 (en) 2005-08-01

Family

ID=22491816

Family Applications (2)

Application Number Title Priority Date Filing Date
DK05006494T DK1593387T3 (en) 1999-06-23 2000-06-22 Compositions for the treatment of uninhibited interpersonal and behavioral disorders
DK00947924T DK1185294T3 (en) 1999-06-23 2000-06-22 Peptides for the treatment of attenuated interpersonal and behavioral disorders

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK05006494T DK1593387T3 (en) 1999-06-23 2000-06-22 Compositions for the treatment of uninhibited interpersonal and behavioral disorders

Country Status (14)

Country Link
US (2) US7387778B2 (en)
EP (2) EP1185294B1 (en)
JP (1) JP2003512302A (en)
CN (1) CN1189211C (en)
AT (2) ATE414529T1 (en)
AU (1) AU6154700A (en)
CA (1) CA2376935A1 (en)
CY (1) CY1108745T1 (en)
DE (2) DE60040878D1 (en)
DK (2) DK1593387T3 (en)
ES (2) ES2315753T3 (en)
NZ (1) NZ516477A (en)
PT (2) PT1185294E (en)
WO (1) WO2001000221A2 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6589750B2 (en) * 1997-02-20 2003-07-08 Institut Pasteur Therapeutic use of the SMR1 protein, the SMR1 maturation products, specifically the QHNPR pentapeptide as well as its biologically active derivatives
DE60040878D1 (en) 1999-06-23 2009-01-02 Pasteur Institut Compositions for the treatment of impaired interpersonal disorders and behavioral disorders
DK1216707T3 (en) * 2000-12-22 2005-05-09 Pasteur Institut Method for screening ligand molecules that specifically bind to the NEP binding sites of the QHNPR pentapeptide
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
DE602004007105T2 (en) 2003-01-28 2008-02-28 Microbia Inc., Cambridge COMPOSITION FOR THE TREATMENT OF GASTROINTESTINAL DISORDER
HUE016435T4 (en) 2004-03-19 2017-01-30 Pasteur Institut Peptides derived from human BPLP protein, polynucleotides coding for said peptides and antibodies directed against said peptides
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
AU2008261102B2 (en) 2007-06-04 2013-11-28 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
RU2542365C2 (en) * 2008-04-07 2015-02-20 Энститю Пастёр Opiorphin peptide derivatives as potential inhibitors of ectopeptidases, participating in degradation of enkephalins
FR2931362B1 (en) 2008-05-26 2017-08-18 Pasteur Institut OPIORPHINE FOR USE AS A PSYCHOSTIMULANT.
EP2328910B1 (en) 2008-06-04 2014-08-06 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP3241839B1 (en) 2008-07-16 2019-09-04 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
CA2645452A1 (en) * 2008-11-28 2010-05-28 Institut Pasteur Use of basic prolin-rich lacrimal gene products, such as opiorphin, as a biomarker
CA2745694C (en) 2008-12-03 2018-03-27 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase c agonists and methods of use
DE102009039655B3 (en) 2009-09-02 2011-03-31 ITT Mfg. Enterprises, Inc., Wilmington UV disinfection device for waste water and drinking water with a cleaning device
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
MX357121B (en) 2011-03-01 2018-06-27 Synergy Pharmaceuticals Inc Star Process of preparing guanylate cyclase c agonists.
WO2014151206A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
AU2014235209B2 (en) 2013-03-15 2018-06-14 Bausch Health Ireland Limited Guanylate cyclase receptor agonists combined with other drugs
BR112015030326A2 (en) 2013-06-05 2017-08-29 Synergy Pharmaceuticals Inc ULTRAPURE GUANYLATE CYCLASE C AGONISTS, METHOD OF MANUFACTURING AND USING THEM
GB201607814D0 (en) 2016-05-04 2016-06-15 5D Health Prot Group Ltd Anti-microbial compositions

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8327966D0 (en) * 1983-10-19 1983-11-23 Nyegaard & Co As Chemical compounds
FR2637600B1 (en) * 1988-10-11 1992-03-06 Pasteur Institut PEPTIDES AND POLYPEPTIDES FROM THE RAT SUB-MAXILLARY GLAND, CORRESPONDING MONOCLONAL AND POLYCLONAL ANTIBODIES, HYBRIDOMAS AND APPLICATIONS THEREOF FOR DIAGNOSIS, DETECTION OR THERAPEUTIC PURPOSES
US5589189A (en) * 1994-09-14 1996-12-31 Nexstar Pharmaceuticals, Inc. Liposome dispersion
US6589750B2 (en) * 1997-02-20 2003-07-08 Institut Pasteur Therapeutic use of the SMR1 protein, the SMR1 maturation products, specifically the QHNPR pentapeptide as well as its biologically active derivatives
KR100353014B1 (en) * 1998-11-11 2002-09-18 동아제약 주식회사 Pyrazolopyrimidinone derivatives for the treatment of impotence
US6455564B1 (en) * 1999-01-06 2002-09-24 Pharmacia & Upjohn Company Method of treating sexual disturbances
DE60040878D1 (en) 1999-06-23 2009-01-02 Pasteur Institut Compositions for the treatment of impaired interpersonal disorders and behavioral disorders
DK1216707T3 (en) 2000-12-22 2005-05-09 Pasteur Institut Method for screening ligand molecules that specifically bind to the NEP binding sites of the QHNPR pentapeptide

Also Published As

Publication number Publication date
EP1593387B1 (en) 2008-11-19
US20030186870A1 (en) 2003-10-02
DE60019106T2 (en) 2006-02-16
PT1593387E (en) 2009-03-18
WO2001000221A2 (en) 2001-01-04
CA2376935A1 (en) 2001-01-04
JP2003512302A (en) 2003-04-02
CY1108745T1 (en) 2014-04-09
AU6154700A (en) 2001-01-31
WO2001000221A3 (en) 2001-05-03
ATE291927T1 (en) 2005-04-15
CN1189211C (en) 2005-02-16
DE60040878D1 (en) 2009-01-02
NZ516477A (en) 2004-02-27
EP1185294B1 (en) 2005-03-30
US7387778B2 (en) 2008-06-17
EP1593387A1 (en) 2005-11-09
ES2315753T3 (en) 2009-04-01
ES2238299T3 (en) 2005-09-01
EP1185294A2 (en) 2002-03-13
US20030078200A1 (en) 2003-04-24
ATE414529T1 (en) 2008-12-15
DE60019106D1 (en) 2005-05-04
PT1185294E (en) 2005-08-31
DK1593387T3 (en) 2009-03-02
CN1356906A (en) 2002-07-03

Similar Documents

Publication Publication Date Title
CY1108745T1 (en) PATIENTS FOR THERAPEUTIC PATIENTS BAD BEHAVIOR BETWEEN PERSONS
TW200510416A (en) P38 inhibitors and methods of use thereof
HRP20020593B1 (en) Brain, spinal and nerve injury treatment
WO2004019884A3 (en) Agents and methods for enhancing bone formation
HK1080467A1 (en) Benzofuran and benzothiophene derivatives useful in the treatment of hyper-proliferative disorders
NO20050851L (en) Caspase Inhibitors and Uses thereof
SE9803710D0 (en) Use of certain drugs for treating nerve root injury
CY1112238T1 (en) ANTI-KINESIN SUSPENSIONS AND METHODS OF USING THESE
ATE433973T1 (en) AZOLYLAMINOAZINES AS INHIBITORS OF PROTEIN KINASES
ATE325612T1 (en) USE OF HYDROXYETHYL RUTOSIDES TO TREAT COLD SYMPTOMS, ALLERGIC RHINITIS SYMPTOMS AND RESPIRATORY INFECTIONS
ATE430193T1 (en) RECOMBINANT ALPHA-L-IDURONIDASE AND TREATMENT OF DEFICIENCY DISEASES CAUSED BY IT
MXPA04001187A (en) Interleukin-1 receptors in the treatment of diseases.
TNSN06403A1 (en) 3-B-D-RIBOFURANOSYLTHIAZOLO[4,5-d]PYRIDIMINE NUCLEOSIDES AND USES THEREOF
WO2005020928A3 (en) Agents and methods for enhancing bone formation by oxysterols in combination with bone morphogenic proteins
MY141528A (en) Anilinopyrazole derivatives useful for the treatment of diabetes
DE60008753D1 (en) USE OF NAALADASE INHIBITORS FOR THE TREATMENT OF ANXIETIES AND MEMORY DISORDER
ATE541565T1 (en) TOPICAL USE OF MUSCARINIC AND OPIOID AGENTS FOR THE TREATMENT OF TINNITUS
DE602004028574D1 (en) COMPOSITIONS AND METHODS FOR TREATING IRRITATION SYNDROME AND NONULCEREOUS DYSPEPSY
TR200200278T2 (en) Calcilitic compositions
DE60142786D1 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANDIDOSES
MXPA04010816A (en) New uses of substituted aminoalkanephosphonic acids.
RS20060023A (en) Use of soluble cd164 in inflammatory and/or autoimmune disorders
UA85187C2 (en) 2-aminobenzoyl derivatives
TW200501958A (en) A therapeutic agent for treating a behavioral disorder
ATE399544T1 (en) SYNERGISTIC COMPOSITION CONTAINING ROFLUMILAST AND (R,R)-FORMOTEROL